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Abstract In previous studies we have showed that somatostatin
(SST) inhibits cell division, mitogen-activated protein (MAP)
kinase and Ras activity in the human neuroblastoma cell line
SY5Y. In the present study, we have assessed the role of a series
of SST analogs, three of which were selective for SSTR1,
SSTR2 or SSTR5, in these cellular events. All the analogs
inhibited forskolin-induced cAMP accumulation. Selective sti-
mulation of SSTR1 or SSTR2 but not of SSTR5 inhibited
platelet-derived growth factor (PDGF)-induced [3H]thymidine
incorporation. The three analogs inhibited PDGF-stimulated
MAP kinase activity, at least at an early time. In contrast, none
of the analogs used individually was able to inhibit PDGF-
stimulated Ras activity. A combined stimulation of SSTR2 and
SSTR5 was necessary to obtain a significant inhibitory effect,
suggesting the possibility of receptor heterodimerization. These
results indicate that SST inhibition of Ras and MAP kinase
activities takes place via different pathways and that SST
inhibition of PDGF-induced cell proliferation occurs via a Ras-
independent pathway. ß 2000 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Somatostatin (SST) exerts a variety of physiological actions
including inhibition of cell proliferation and hormone secre-
tion via both indirect and direct mechanisms [1]. Interestingly,
SST has also recently been suggested to possess antiangiogenic
properties in rodents [2]. Based on experimental evidence from
animals and cell cultures studies, the use of SST or the longer
lasting analogs octeotride and lanreotide to suppress tumor
cell proliferation in humans has been proposed [3]. However,
clinical trials in cancer patients to date have not been very
encouraging so that the therapeutic application of SST and
the analogs is presently limited to the treatment of neuroen-
docrine tumors. Despite these negative results, study of the
mechanisms underlying the antiproliferative action of SST
might help to ¢nd new therapeutic approaches to cancer treat-
ment. All the actions of SST are mediated by its interaction
with speci¢c membrane receptors of which ¢ve members have
been cloned [4]. All the cloned SST receptors (SSTRs) belong
to the family of seven transmembrane domain receptors, tra-
ditionally coupled to G proteins [4]. These receptors activate a
variety of intracellular signals including inhibition of adenyl-
ate cyclase and Ca2 channels and activation of K channels
and phosphatase activity. Pertussis toxin (PTx)-sensitive G
proteins couple SSTR subtypes to their e¡ectors [4]. Since
the cloning of the ¢ve distinct SSTR subtypes, attempts
have been made to attribute speci¢c biological functions to
each subtype. However, the lack of selective ligands has made
it di⁄cult to identify distinct functions for a particular recep-
tor subtype. We have previously shown [5,6] that SST was
capable of inhibiting cell proliferation, mitogen-activated pro-
tein (MAP) kinase and Ras activity in the human neuroblas-
toma cell line SY5Y. The very recent development of speci¢c
ligands for the SSTR1, SSTR2 and SSTR5 subtypes has al-
lowed us to investigate the role of each of these receptors in
the cellular processes a¡ected by SST in SY5Y cells.
2. Materials and methods
2.1. Cell culture
The human neuroblastoma cell line SY5Y was grown in RPMI
1640 medium supplemented with 10% heat-inactivated fetal bovine
serum and kept at 37‡C in a humidi¢ed atmosphere of 5% CO2 in air.
2.2. RNA isolation and reverse transcription-polymerase chain reaction
(RT-PCR)
Total RNA was isolated using a RNeasy total RNA isolation kit
(Qiagen), following the supplier’s protocol. cDNA was synthesized
using M-MLV reverse transcriptase (Promega) with oligo(dT) primers
and 10 ng of cDNA was subsequently used in the PCR reaction.
Optimal temperature and cycling conditions were established for all
¢ve hSSTRs according to Panetta and Patel [7]. Ampli¢ed DNA frag-
ments were visualized by 1.5% agarose gel electrophoresis. The prim-
ers used were described in [7]. Expected lengths for the ampli¢ed
products were the following: SSTR1, 993 bp; SSTR2, 892 bp;
SSTR3, 221 bp; SSTR4, 276 bp; SSTR5, 298 bp. The speci¢city of
the ampli¢ed SSTR products was validated by sequencing (MWG-
Biotech GmbH, Germany).
2.3. Intracellular cAMP assay
Cells were plated in 24-well dishes at a density of 2.5U105 cells/
well. Before stimulation for 20 min with 50 WM forskolin in the
presence of the analogs, the cells were incubated for 5 min with
1 mM isobutylmethylxanthine. Intracellular cAMP levels were quan-
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ti¢ed by radioimmunoassay using a commercial kit (Amersham Phar-
macia Biotech, UK) after 95% ethanol extraction.
2.4. Proliferation assay
Quiescent SY5Y cells, plated at a density of 2U104 cells/well in 96-
well dishes, were stimulated for 24 h with 20 ng/ml platelet-derived
growth factor (PDGF) in the presence of the analogs. [3H]Thymidine
(1 WCi/well, speci¢c activity 2 Ci/mmol, Amersham Pharmacia Bio-
tech, UK) was added during the last 6 h of incubation. The cells were
extracted in 10% trichloroacetic acid (TCA) and the radioactivity in-
corporated into TCA-insoluble material was evaluated after solubili-
zation in 0.5 M NaOH.
2.5. MAP kinase activity assay
Quiescent SY5Y cells, plated in 60-mm Petri dishes, were washed
with phosphate-bu¡ered saline and lysed in 600 Wl of lysis bu¡er as
previously described [6]. MAP kinase was then immunoprecipitated
from the lysates using a polyclonal anti-ERK2 antibody (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and protein A-Sepharose
beads. Immunocomplex kinase assay was performed as described in
[6] using 250 Wg/ml myelin basic protein (MBP, Gibco BRL, Grand
Island, NY, USA) and [Q-32P]ATP (3.0 WCi/sample; speci¢c activity
3000 Ci/mmol; Amersham Pharmacia Biotech, UK) as substrates. An
aliquot of the supernatants was transferred onto P81 phosphocellulose
paper squares and after ¢ve washes in 0.75% phosphoric acid the
radioactivity associated with the squares was determined by liquid
scintillation counting.
2.6. Ras activity assay
GST-RBD (aa 51^131 of Raf-1) fusion protein was isolated in our
laboratory from pGEX 2T-RBD induced with IPTG as previously
described [8]. Activated Ras-GTP was precipitated from whole cell
lysates prepared in lysis bu¡er (containing 50 mM HEPES^NaOH
pH 7.4, 250 mM NaCl, 5 mM MgCl2, 10% glycerol, 0.5 mM phen-
ylmethylsulfonyl £uoride, 10 Wg/ml aprotinin and 10 Wg/ml leupeptin)
with 20 Wl glutathione agarose beads coupled with GST fusion protein
containing the Ras binding domain (RBD) of Raf. After 12% SDS^
PAGE, active Ras protein was detected by Western blotting using
monoclonal anti-Ras antibodies (Transduction Laboratories, Lexing-
ton, KY, USA).
3. Results
3.1. SSTR subtype expression in SY5Y cells
SSTR subtype mRNAs were detected in SY5Y cells by RT-
PCR using speci¢c primers [7] (Fig. 1). The size of each PCR
product corresponded to the predicted length of the cDNA
fragment (993 bp, SSTR1; 892 bp, SSTR2; 221 bp, SSTR3;
276 bp, SSTR4; 298 bp, SSTR5). Con¢rmation of the identity
to the SSTR sequences was obtained by sequencing all the
PCR products (data not shown). As can be seen in Fig. 1,
we observed the expression of all ¢ve SSTR subtypes in SY5Y
cells.
3.2. SST analogs
SST binds to the ¢ve receptor subtypes with high a⁄nity
and little selectivity. A large number of analogs have been
synthesized in the attempt to develop speci¢c compounds
with more selective actions and greater metabolic stability
than the native hormone.
SST analogs Bim 23014, Bim 23120, Bim 23190, Bim 23197,
Bim 23206, Bim 23268 and Bim 23745 were synthesized and
supplied by Biomeasure, Inc. (Milford, MA, USA).
Receptor binding assays were performed using membrane
preparations obtained from transfected CHO-K1 cells ex-
pressing the human SSTR subtypes 1^5 as described previ-
ously [9]. The IC50 values for the compounds used in our
experiments are shown in Table 1. As already known, Bim
23014 (lanreotide/somatuline introduced into clinical use sev-
eral years ago) binds preferentially to SSTR2 with moderate
SSTR5 activity. Bim 23190 and Bim 23197 are more potent at
SSTR2 with selectivity comparable to Bim 23014. Bim 23268
has high a⁄nity for SSTR5 with some activity at all the other
subtypes. Bim 23745, Bim 23120 and Bim 23206 are fully
selective analogs for the SSTR1, 2 and 5 subtypes respectively,
as can be seen from the IC50s presented in Table 1. This is the
¢rst report showing the binding a⁄nities for these three ana-
logs and the method used for determining the Ki is as reported
in [9]. In our experiments these three compounds were used as
speci¢c ligands for the individual SST receptor subtypes 1, 2
and 5. There are still no SSTR3- and SSTR4-selective ago-
nists.
3.3. SST analogs and cAMP formation
All ¢ve receptor subtypes couple in an inhibitory fashion to
adenylate cyclase via a PTx-sensitive G protein [4]. Fig. 2
Fig. 1. SSTR subtypes expressed in SY5Y cells. RT-PCR was per-
formed as described in Section 2. The size of each PCR product is
shown on the right side of the photograph.
Table 1
Binding a⁄nity of SST and its analogs for the cloned hSSTR subtypes
IC50 (nM)
SSTR1 SSTR2 SSTR3 SSTR4 SSTR5
Bim 23745 42 s 1000 s 1000 s 1000 1480
Bim 23120 1000 0.34 412 1000 213.5
Bim 23206 1152 166 1000 1618 2.4
Bim 23190 5210 0.35 215 7537 11.2
Bim 23197 6016 0.19 26.8 3897 9.8
Bim 23268 12 28 5.5 36 0.42
Bim 23014 2129 0.75 98 1826 12.7
SST-14 1.95 0.25 1.2 1.77 1.41
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shows that all the analogs tested inhibited forskolin-stimu-
lated cAMP accumulation in SY5Y cells. Maximal accumu-
lation of cAMP by 50 WM forskolin, set at 100%, was reduced
to 66% after pretreatment with SST, i.e. the inhibition induced
by the native hormone was 34%. The inhibition of cAMP
accumulation by the analogs was 32%, 22% and 28% for
Bim 23745 (200 nM), Bim 23120 (20 nM) and Bim 23206
(20 nM), respectively. The inhibition by the other non-selec-
tive analogs ranged between 34 and 36%. These results imply
that: (1) SST receptors expressed in SY5Y cells are function-
ally active; (2) all the analogs tested behave as SSTR agonists.
3.4. SST analogs and cell proliferation
To analyze the speci¢c biological function coupled to SSTR
subtypes, SY5Y cell proliferation was tested in the presence of
SSTR1, 2 or 5 agonists (Fig. 3). Bim 23120 (20 nM) inhibited
PDGF-stimulated [3H]thymidine incorporation to the same
extent (60%) as SST. Bim 23745 (200 nM) was a little less
e⁄cient (42% inhibition), while Bim 23206 (20 nM) did not
Fig. 2. E¡ect of SST and its analogs on intracellular cAMP levels.
SY5Y cells were treated for 20 min with 50 WM forskolin in the ab-
sence or in the presence of the following drugs: Bim 23745 (200
nM), Bim 23120 (20 nM), Bim 23206 (20 nM), Bim 23190 (20 nM),
Bim 23197 (100 nM), Bim 23268 (200 nM), Bim 23014 (20 nM) and
SST (10 nM). The intracellular cAMP levels were assayed by radio-
immunoassay after ethanol extraction. Data are expressed as percent
maximal stimulation observed with forskolin alone. Each histogram
is the mean þ S.E.M. of three independent experiments, each per-
formed in duplicate. *P6 0.005, Student’s t-test.
Fig. 3. E¡ect of SST and its analogs on PDGF-induced DNA syn-
thesis. Quiescent SY5Y cells were stimulated with 20 ng/ml PDGF
in the absence (open bar) or in the presence of Bim 23745 (200 nM,
diagonal bar), Bim 23120 (20 nM, horizontal bar), Bim 23206 (20
nM, cross-hatched bar) or SST (10 nM, solid bar). [3H]Thymidine
incorporation by the cells was evaluated as described in Section 2.
Results are expressed as percent maximal stimulation induced by
PDGF and are the mean þ S.E.M. of 3^5 independent experiments,
each performed in triplicate. *P6 0.005, Student’s t-test.
Fig. 4. E¡ect of SST and its analogs on PDGF-induced MAP ki-
nase activity. A: Quiescent SY5Y cells were treated for 8 min with
Bim 23745 (200 nM, diagonal bar), Bim 23120 (20 nM, horizontal
bar), Bim 23206 (20 nM, cross-hatched bar) or SST (10 nM, solid
bar) before stimulation for 5 min with 20 ng/ml PDGF (open bar:
no Bim). MAP kinase activity was evaluated by immunocomplex ki-
nase assay as described in Section 2. Results are expressed as per-
cent maximal stimulation induced by PDGF and are the mean þ
S.E.M. of four independent experiments, each performed in dupli-
cate. *P6 0.005, Student’s t-test. B: Cells were treated with PDGF
20 ng/ml for the indicated times in the absence (8) or in the pres-
ence of SST 10 nM (F) or Bim 23206 20 nM (E). MAP kinase ac-
tivity was evaluated as in A. Results are expressed as cpm of 32P in-
corporated in MBP and are the mean þ S.D. of a representative
experiment which was repeated once with similar results.
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a¡ect [3H]thymidine incorporation at all. These data indicate
that, while the receptor subtypes 1 and 2 individually stimu-
lated are capable of inhibiting cell proliferation stimulated by
PDGF, subtype 5 is ine¡ective.
3.5. SST analogs and MAP kinase activity
MAP kinase as well as Ras activities are considered crucial
events in growth factor signalling [10]. We have previously
reported that SST inhibited serum- and PDGF-stimulated
MAP kinase activity in SY5Y cells [5,6]. Fig. 4A shows that
the analogs speci¢c for the receptor subtypes 1, 2 and 5 in-
hibited the PDGF-stimulated MAP kinase activity by 61, 36
and 48%, respectively. For this assay, overnight serum-de-
Fig. 5. E¡ect of SST and its analogs on PDGF-induced Ras activ-
ity. A: Serum-deprived SY5Y cells were pretreated for 8 min with
Bim 23745 (200 nM), Bim 23120 (20 nM), Bim 23206 (20 nM) or
SST (10 nM) before stimulation with PDGF (20 ng/ml) for 4 min.
Ras was identi¢ed by a⁄nity precipitation with GST-RBD followed
by immunoblotting (upper panel) and by immunoblotting of total
cell lysates (lower panel) using anti-Ras antibodies. B: The experi-
ment was performed as in A, but the analogs at the concentrations
indicated above were added simultaneously in the following combi-
nation: Bim 23745+Bim 23120, lane 5; Bim 23120+Bim 23206, lane
6; Bim 23745+Bim 23206, lane 7. SST (lane 3) and Bim 23014 (lane
4) were added at concentrations of 10 nM and 20 nM, respectively.
Ras was identi¢ed as described in A. Each type of experiment was
repeated three times with similar results.
Fig. 6. Di¡erential e¡ect of PTx treatment on SST- and analog-
mediated inhibition of MAP kinase and Ras activity both induced
by PDGF. A: Serum-deprived SY5Y cells were incubated for 4 h in
the presence (open bars) or in the absence (solid bars) of 100 ng/ml
PTx. The experiments and the evaluation of the MAP kinase activ-
ity were then performed as described in Fig. 4. Results are ex-
pressed as percent maximal stimulation induced by PDGF and are
the mean þ S.E.M. of three independent experiments, each per-
formed in duplicate. B: Serum-deprived SY5Y cells, preincubated
where indicated with PTx as in A, were treated with 10 nM SST or
with the combination 20 nM Bim 23120+20 nM Bim 23206 before
stimulation with 20 ng/ml PDGF for 4 min. Ras activity was mea-
sured as described in Fig. 5. This experiment was repeated three
times with similar results.
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prived cells were preincubated for 8 min with SST (10 nM) or
with the three analogs individually at the concentrations pre-
viously indicated, and then stimulated with PDGF (20 ng/ml)
for 5 min. MAP kinase activity was measured by immuno-
complex kinase assay as described in Section 2.
Also in Western blot experiments using antibodies against
the phosphorylated forms of ERK-1 and ERK-2 the analogs
decreased the phosphorylation levels of both the enzymes
(data not shown).
We have previously described that the analog speci¢c for
SSTR5 did not a¡ect cell proliferation (Fig. 3) and yet here it
does inhibit MAP kinase activity. Since it has been suggested
that a prolonged activation of MAP kinase is needed for
stimulation of cell proliferation [11], we measured the e¡ect
of Bim 23206 after a longer time of PDGF stimulation. Fig.
4B shows the typical biphasic kinetics of MAP kinase activity
stimulated by growth factors (in our case PDGF) [11]. It can
be seen that while SST was capable of inhibiting MAP kinase
activity even after a prolonged (1 and 3 h) stimulation with
PDGF, the analog did not and at these later times MAP ki-
nase activity was back to control levels. Thus, it is possible to
speculate that the lack of e¡ect of Bim 23206 on cell prolif-
eration could be ascribed to its inability to induce a long-
lasting MAP kinase inhibition.
3.6. SST analogs and Ras activity
We have previously shown [6] that SST inhibited the
PDGF-stimulated Ras activity by an assay of cell lysate im-
munoprecipitation with GST-RBD (the minimal Ras binding
domain of Raf) which binds to the active form of Ras. Fig.
5A shows that the single analogs were not capable of inhibit-
ing PDGF-stimulated Ras activity. Only the combined action
of the analogs speci¢c for SSTR2 and SSTR5 (but not of
those speci¢c for SSTR1 and 2 or SSTR1 and 5) induced a
dramatic decrease of the active Ras (Fig. 5B). Moreover, the
analog Bim 23014, which displays high a⁄nity for SSTR2 and
moderate activity for SSTR5, depressed Ras activity. The ana-
log Bim 23197, which possesses a pro¢le similar to Bim 23014,
behaved in the same way (data not shown). Thus, the simul-
taneous stimulation of SST receptor subtypes 2 and 5 is
needed to obtain the inhibitory e¡ect on Ras. Equal amounts
of total Ras proteins were subjected to the RBD binding assay
as shown by immunoblotting of an aliquot of total cell lysate
followed by detection with anti-Ras antibodies (lower panel).
Our results indicate that SST may inhibit MAP kinase and
Ras activity via two di¡erent mechanisms (Scheme 1). This
conclusion is further supported by the experiments presented
in Fig. 6. SY5Y cells either were or were not pretreated with
PTx for 4 h and then assayed for MAP kinase (Fig. 6A) and
Ras (Fig. 6B) activity stimulated by PDGF in the presence or
in the absence of SST or the analogs. It can be seen that while
the inhibitory action of SST and SST analogs on MAP kinase
is abolished by PTx, Ras activity is still inhibited by the hor-
mone and analogs even in the presence of the toxin.
4. Discussion
Five distinct SSTR subtypes have been cloned and often
more than one subtype is expressed in the same target cell ;
therefore it is reasonable to assume that each SSTR subtype
could serve distinct biological functions and couple to distinct
e¡ectors via speci¢c mechanisms. It is also reasonable to think
that there could be additional functions modulated by the
combined action of two or more SSTR subtypes.
Two factors allowed us to begin the di⁄cult task of de¢ning
speci¢c roles for SSTR subtypes. First, three selective ligands
for SSTR1, 2 and 5 were made available to us. Second, we
had at our disposal in the laboratory a human neuroblastoma
cell line SY5Y where SST suppresses cell proliferation and in
which all ¢ve SSTR subtypes are expressed, according to our
RT-PCR studies. With these tools it was possible to begin to
at least partially unravel which SSTR subtype(s) is responsible
for the SST antiproliferative e¡ect and which signalling mech-
anisms are involved.
Scheme 1. Schematic representation of the hypothetical mechanisms suggested for the inhibitory e¡ect of SST on Ras and MAP kinase activ-
ities.
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Up to now, the role of a receptor subtype on cell responses
has been studied in cells transfected with individual SSTR
subtypes where the high number of receptors expressed may
favor a less selective coupling to the e¡ectors. In our case we
are measuring the response of the native receptors in their
natural environment. The receptor subtypes considered are
functional since they respond to the application of the analogs
by decreasing forskolin-stimulated cAMP accumulation. Re-
garding the antiproliferative action, we have shown that the
stimulation of SSTR1 and SSTR2 individually, but not of
SSTR5, is su⁄cient to inhibit cell proliferation stimulated
by PDGF. SSTR2 stimulation was as e¡ective as SST itself,
while the SSTR1 ligand induced a slightly smaller inhibition.
The lack of e¡ect of the SSTR5 ligand as antiproliferative
agent in this case could be ascribed to its inability to induce
a long-lasting inhibition of MAP kinase activity stimulated by
PDGF. It has in fact been suggested that the prolonged phase
of MAP kinase activation by growth factors is needed to
allow the complex cellular machinery for cell division to set
in motion [11]. SSTR5 was able to inhibit only the early phase
of enzyme activation, allowing the late phase to occur unen-
cumbered. From the literature, it appears that there are di¡er-
ences in the cellular regulation of the ¢ve SSTRs and a di¡er-
ent pattern of internalization has been described for each of
them [12,13]. One can hypothesize that in our cells SSTR5
receptors may undergo a desensitization and internalization
faster than the other two subtypes thus preventing a long-
term action.
In our opinion, one of the most interesting ¢ndings of this
report is the need for a combined action of SSTR2 and 5 (and
not of SSTR1 and 2 or SSTR1 and 5) to inhibit Ras activity.
The formation of dimers for tyrosine kinase receptors is well
assessed but it has only recently been proposed for G protein-
coupled receptors (for a review and a comment see [14,15]).
Recent evidence that some members of the SSTRs family
undergo heterodimerization [16] is in line with our result.
The dimeric association has been shown to alter some func-
tional properties of the receptors such as binding a⁄nity and
internalization [16]. This report and our present results sug-
gest that multiple SSTR subtypes expressed in the same cells
are not simply redundant but interact functionally and specif-
ically with each other (in our hands only SSTR2 and 5 com-
bination inhibits Ras activity) to provide greater signalling
diversity.
A further interpretation of our results is that MAP kinase
inhibition occurring after individual SSTR stimulation is
mediated by a di¡erent pathway than Ras inhibition. This
conclusion is con¢rmed by the di¡erent sensitivity to PTx
displayed by the analogs on MAP kinase and Ras activity
inhibition. We had previously reported that SST inhibition
of Ras activity is insensitive to PTx treatment and suggested
that either a PTx-insensitive G protein is associated with
SSTR or that there is a direct association of the SSTR with
the e¡ector bypassing the requirement of a G protein [6]. This
putative G protein-independent SSTR^e¡ector interaction
might involve a PDZ domain. The consensus sequence for
binding PDZ domains (T/SXV/L/I) is present on the C-termi-
nal tail of both SSTR2 and 5 subtypes. An interaction be-
tween a PDZ bearing protein (CortBP1) and the rat SSTR2
subtype has been recently reported in transfected human em-
bryonic kidney cells [17]. Experiments to further elucidate
these mechanisms are under way in our laboratory. The
SST inhibition of MAP kinase activity is, in contrast, PTx-
sensitive and involves the interaction of a PTx-sensitive G
protein with the e¡ector. From our results it also derives
that Ras activity is not correlated with MAP kinase activity
nor with cell proliferation in SY5Y cells.
In conclusion, the data presented here suggest that the ac-
tion of SST is very complex. Its interaction with the speci¢c
receptors and possibly with receptor heterodimers produces a
variety of intracellular signals via diverse mechanisms which
may very well explain the multiplicity of SST e¡ects on target
cells. Due to this complexity, it is important to identify spe-
ci¢c roles for the receptor subtypes. Further studies with se-
lective analogs will lead to a better understanding of SSTR
functions and to the discovery of compounds able to target
speci¢c physiological e¡ects and pathological conditions.
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